{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:03:38Z","timestamp":1793703818134,"version":"4.5.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Alzheimerforeningens Forskningsfond"},{"DOI":"10.13039\/501100006088","name":"Direkt\u00f8r Emil C. Hertz og Hustru Inger Hertz' Fond","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006088","id-type":"DOI","asserted-by":"crossref"}]},{"name":"M.L. J\u00f8rgensen og Gunnar Hansens Foundation"},{"name":"Rigshospitalets Forskningspulje"},{"DOI":"10.13039\/501100005747","name":"A.P. M\u00f8ller og Hustru Chastine Mc-Kinney M\u00f8llers Fond til almene Formaal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010319","name":"Michaelsen Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Absalon Foundation of May 1st 1978"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01892-7","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:46:16Z","timestamp":1762962376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic value of plasma biomarkers in early Alzheimer\u2019s disease: a longitudinal clinical and neuroimaging study"],"prefix":"10.1186","volume":"17","author":[{"given":"Frederikke Kragh","family":"Clemmensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias Holsey","family":"Gramkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gonzalez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a Lessa","family":"Benedet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00fcbra","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Traichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto M\u00f8lby","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja Hviid","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian Steen","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen Gregers","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"11","key":"1892_CR1","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","volume":"65","author":"HJ Aizenstein","year":"2008","unstructured":"Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509\u201317.","journal-title":"Arch Neurol"},{"issue":"11","key":"1892_CR2","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28(11):2381\u20137.","journal-title":"Nat Med"},{"issue":"7","key":"1892_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58070952","volume":"58","author":"J Cummings","year":"2022","unstructured":"Cummings J, Kinney J. Biomarkers for Alzheimer\u2019s disease: context of use, qualification, and roadmap for clinical implementation. Medicina (Kaunas). 2022;58(7):952.","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"1892_CR4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.14283\/jpad.2023.68","volume":"10","author":"D Angioni","year":"2023","unstructured":"Angioni D, Hansson O, Bateman RJ, Rabe C, Toloue M, Braunstein JB, et al. Can we use blood biomarkers as entry criteria and for monitoring drug treatment effects in clinical trials? A report from the EU\/US CTAD task force. J Prev Alzheimers Dis. 2023;10(3):418\u201325.","journal-title":"J Prev Alzheimers Dis"},{"issue":"16","key":"1892_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13195-024-01593-7","volume":"19","author":"K G\u00f6tze","year":"2024","unstructured":"G\u00f6tze K, Vrillon A, Dumurgier J, Indart S, Sanchez-Ortiz M, Slimi H, et al. Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting study. Alzheimers Res Ther. 2024;19(16):231.","journal-title":"Alzheimers Res Ther"},{"issue":"17","key":"1892_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13195-025-01745-3","volume":"2","author":"Y Qiu","year":"2025","unstructured":"Qiu Y, Jacobs DM, Messer K, Salmon DP, Wellington CL, Stukas S, et al. Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer\u2019s disease. Alzheimers Res Ther. 2025;2(17):97.","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"1892_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","volume":"76","author":"N Mattsson","year":"2019","unstructured":"Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2019;76(7):791\u20139.","journal-title":"JAMA Neurol"},{"issue":"5","key":"1892_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K, for the Alzheimer\u2019s Disease Neuroimaging Initiative. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology. 2017;74(5):557\u201366.","journal-title":"JAMA Neurology."},{"issue":"3","key":"1892_CR9","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/brain\/awac407","volume":"146","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz F, Turton M, Kac PR, Smirnov D, Premi E, Ghidoni R, et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer\u2019s disease-type neurodegeneration. Brain. 2023;146(3):1152\u201365.","journal-title":"Brain"},{"issue":"10","key":"1892_CR10","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1002\/alz.13156","volume":"19","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz F, Dias A, Turton M, Magalh\u00e3es R, Kac PR, Correia M, et al. Preanalytical stability of plasma\/serum brain-derived tau. Alzheimers Dement. 2023;19(10):4764\u201370.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1892_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47286-5","volume":"15","author":"F Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz F, Kirsebom BE, Contador J, Tanley JE, Selnes P, G\u00edslad\u00f3ttir B, et al. Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer\u2019s disease. Nat Commun. 2024;15(1):2908.","journal-title":"Nat Commun"},{"key":"1892_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-025-00835-z","author":"R Ossenkoppele","year":"2025","unstructured":"Ossenkoppele R, Salvad\u00f3 G, Janelidze S, Pichet Binette A, Bali D, Karlsson L, et al. Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials. Nat Aging 5, 883\u2013896 (2025). https:\/\/doi.org\/10.1038\/s43587-025-00835-z","journal-title":"Nat Aging"},{"issue":"9","key":"1892_CR13","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, Salvad\u00f3 G, Ortiz-Romero P, Montoliu-Gaya L, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28(9):1797\u2013801.","journal-title":"Nat Med"},{"issue":"11","key":"1892_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213676","volume":"104","author":"F Gonzalez-Ortiz","year":"2025","unstructured":"Gonzalez-Ortiz F, Kirsebom BE, Yakoub Y, Gundersen JK, P\u00e5lhaugen L, Waterloo K, et al. Associations between changes in levels of phosphorylated tau and severity of cognitive impairment in early Alzheimer disease. Neurology. 2025;104(11):e213676.","journal-title":"Neurology"},{"issue":"2","key":"1892_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s43587-023-00565-0","volume":"4","author":"Y Guo","year":"2024","unstructured":"Guo Y, You J, Zhang Y, Liu WS, Huang YY, Zhang YR, et al. Plasma proteomic profiles predict future dementia in healthy adults. Nat Aging. 2024;4(2):247\u201360.","journal-title":"Nat Aging"},{"issue":"12","key":"1892_CR16","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","volume":"79","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79(12):1250\u20139.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1892_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"1892_CR18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/alz.12447","volume":"18","author":"P Chatterjee","year":"2022","unstructured":"Chatterjee P, Pedrini S, Ashton NJ, Tegg M, Goozee K, Singh AK, et al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2022;18(6):1141\u201354.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1892_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14537","volume":"21","author":"Y Yakoub","year":"2025","unstructured":"Yakoub Y, Gonzalez-Ortiz F, Ashton NJ, D\u00e9ry C, Strikwerda-Brown C, St-Onge F, et al. Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window. Alzheimers Dement. 2025;21(2):e14537.","journal-title":"Alzheimers Dement"},{"key":"1892_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101030","volume":"45","author":"PV Martino-Adami","year":"2024","unstructured":"Martino-Adami PV, Chatterjee M, Kleineidam L, Weyerer S, Bickel H, Wiese B, et al. Prognostic value of Alzheimer\u2019s disease plasma biomarkers in the oldest-old: a prospective primary care-based study. The Lancet Regional Health. 2024;45:101030.","journal-title":"The Lancet Regional Health"},{"issue":"6","key":"1892_CR21","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/ene.15762","volume":"30","author":"A Silva-Sp\u00ednola","year":"2023","unstructured":"Silva-Sp\u00ednola A, Lima M, Leit\u00e3o MJ, Bernardes C, Dur\u00e3es J, Duro D, et al. Blood biomarkers in mild cognitive impairment patients: relationship between analytes and progression to Alzheimer disease dementia. Eur J Neurol. 2023;30(6):1565\u201373.","journal-title":"Eur J Neurol"},{"issue":"4","key":"1892_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac155","volume":"4","author":"P Kivis\u00e4kk","year":"2022","unstructured":"Kivis\u00e4kk P, Magdamo C, Trombetta BA, Noori A, Kuo YKE, Chibnik LB, et al. Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. Brain Commun. 2022;4(4):fcac155.","journal-title":"Brain Commun"},{"issue":"3","key":"1892_CR23","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/brain\/awad330","volume":"147","author":"S De Meyer","year":"2024","unstructured":"De Meyer S, Blujdea ER, Schaeverbeke J, Reinartz M, Luckett ES, Adamczuk K, et al. Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes. Brain. 2024;147(3):936\u201348.","journal-title":"Brain"},{"issue":"477","key":"1892_CR24","doi-asserted-by":"publisher","first-page":"123679","DOI":"10.1016\/j.jns.2025.123679","volume":"15","author":"CS Musaeus","year":"2025","unstructured":"Musaeus CS, Gleerup HS, Clemmensen FK, Sellebjerg F, Hansen MB, S\u00f8ndergaard HB, et al. Serum neurofilament light chain levels are associated with cognitive decline in a consecutive cohort of patients with Alzheimer\u2019s disease. J Neurol Sci. 2025;15(477):123679.","journal-title":"J Neurol Sci"},{"issue":"11","key":"1892_CR25","doi-asserted-by":"publisher","first-page":"7120","DOI":"10.1007\/s00415-024-12674-w","volume":"271","author":"M Mitolo","year":"2024","unstructured":"Mitolo M, Lombardi G, Manca R, Nacmias B, Venneri A. Association between blood-based protein biomarkers and brain MRI in the Alzheimer\u2019s disease continuum: a systematic review. J Neurol. 2024;271(11):7120\u201340.","journal-title":"J Neurol"},{"issue":"1","key":"1892_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-024-01658-7","volume":"17","author":"FK Clemmensen","year":"2025","unstructured":"Clemmensen FK, Gramkow MH, Simonsen AH, Ashton NJ, Huber H, Blennow K, et al. Short-term variability of Alzheimer\u2019s disease plasma biomarkers in a mixed memory clinic cohort. Alzheimer\u2019s Research & Therapy. 2025;17(1):26.","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"1","key":"1892_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13195-025-01692-z","volume":"17","author":"B Arslan","year":"2025","unstructured":"Arslan B, Brum WS, Pola I, Therriault J, Rahmouni N, Stevenson J, et al. The impact of kidney function on Alzheimer\u2019s disease blood biomarkers: implications for predicting amyloid-\u03b2 positivity. Alzheimer\u2019s Research & Therapy. 2025;17(1):48.","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"12","key":"1892_CR28","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1002\/alz.13163","volume":"19","author":"H Huber","year":"2023","unstructured":"Huber H, Ashton NJ, Schieren A, Montoliu-Gaya L, Molfetta GD, Brum WS, et al. Levels of Alzheimer\u2019s disease blood biomarkers are altered after food intake\u2014a pilot intervention study in healthy adults. Alzheimers Dement. 2023;19(12):5531\u201340.","journal-title":"Alzheimers Dement"},{"key":"1892_CR29","first-page":"20","volume":"9","author":"E Lee","year":"2025","unstructured":"Lee E, Kang S, Kim Y, Zetterberg H, Blennow K, Gonzalez Ortiz F, et al. Relationships between medical comorbidities and plasma biomarkers of Alzheimer\u2019s disease reflect increased pathological markers as well as biological variabilities. Alzheimer\u2019s & Dementia. 2025;9:20.","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"4","key":"1892_CR30","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy NR, Salvad\u00f3 G, Schindler SE, He Y, Janelidze S, Collij LE, et al. Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024;30(4):1085\u201395.","journal-title":"Nat Med"},{"issue":"5","key":"1892_CR31","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","volume":"80","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Barth\u00e9lemy NR, He Y, Bateman RJ, Hansson O. Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurol. 2023;80(5):516\u201322.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1892_CR32","doi-asserted-by":"publisher","first-page":"e70143","DOI":"10.1002\/trc2.70143","volume":"11","author":"FK Clemmensen","year":"2025","unstructured":"Clemmensen FK, Gonzalez-Ortiz F, Gramkow MH, Santos C, Zetterberg H, Blennow K, et al. The plasma p-tau217\/BD-tau ratio improves biomarker short-term variability in memory clinic patients. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2025;11(3):e70143.","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"3","key":"1892_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res"},{"issue":"11","key":"1892_CR34","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1212\/01.wnl.0000434309.85312.19","volume":"55","author":"PS Mathuranath","year":"2000","unstructured":"Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR. A brief cognitive test battery to differentiate Alzheimer\u2019s disease and frontotemporal dementia. Neurology. 2000;55(11):1613\u201320.","journal-title":"Neurology"},{"issue":"3","key":"1892_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1892_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"key":"1892_CR37","doi-asserted-by":"publisher","first-page":"138728772513651","DOI":"10.1177\/13872877251365195","volume":"8","author":"SG Hasselbalch","year":"2025","unstructured":"Hasselbalch SG, Andersen BB, Ejlerskov P, Frederiksen KS, Nielsen JE, Nielsen TR, et al. The Danish Dementia Research Centre: Integrating patient care, clinical research, and national educational services. J of Alzheimer\u2019s Dis. 2025;8:13872877251365196.","journal-title":"J of Alzheimer\u2019s Dis"},{"issue":"9","key":"1892_CR38","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1515\/cclm-2023-0191","volume":"61","author":"K Dimopoulos","year":"2023","unstructured":"Dimopoulos K, Simonsen AH, Gramkow MH, Schr\u00f8der M, J\u00f8rgensen NR, Rode L, et al. Measurement of amyloid-\u03b2 1\u201342 in cerebrospinal fluid: a comparison of the second generation Elecsys and INNOTEST. Clin Chem Lab Med (CCLM). 2023;61(9):e182\u20135.","journal-title":"Clin Chem Lab Med (CCLM)"},{"issue":"2","key":"1892_CR39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1515\/cclm-2022-0516","volume":"61","author":"K Blennow","year":"2023","unstructured":"Blennow K, Stomrud E, Zetterberg H, Borlinghaus N, Corradini V, Manuilova E, et al. Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer\u2019s disease. Clin Chem Lab Med (CCLM). 2023;61(2):234\u201344.","journal-title":"Clin Chem Lab Med (CCLM)"},{"issue":"11","key":"1892_CR40","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412\u20134.","journal-title":"Neurology"},{"key":"1892_CR41","unstructured":"International Classification of Diseases, Eleventh Revision (ICD-11), World Health Organization (WHO) 2019\/2021. https:\/\/www.who.int\/standards\/classifications\/classification-of-diseases"},{"issue":"2","key":"1892_CR42","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00259-021-05603-w","volume":"49","author":"E Guedj","year":"2022","unstructured":"Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, et al. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022;49(2):632\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1892_CR43","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuroimage.2012.01.021","volume":"62","author":"B Fischl","year":"2012","unstructured":"Fischl B. FreeSurfer. Neuroimage. 2012;62(2):774\u201381.","journal-title":"Neuroimage"},{"issue":"7","key":"1892_CR44","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213438","volume":"104","author":"E Sanchez","year":"2025","unstructured":"Sanchez E, Coughlan GT, Wilkinson T, Ramirez J, Mirza SS, Baril AA, et al. Association of plasma biomarkers with longitudinal atrophy and microvascular burden on MRI across neurodegenerative and cerebrovascular diseases. Neurology. 2025;104(7):e213438.","journal-title":"Neurology"},{"issue":"3","key":"1892_CR45","doi-asserted-by":"publisher","first-page":"e12490","DOI":"10.1002\/trc2.12490","volume":"10","author":"DC Matthews","year":"2024","unstructured":"Matthews DC, Kinney JW, Ritter A, Andrews RD, Toledano Strom EN, Lukic AS, et al. Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer\u2019s disease patients. Alzheimer\u2019s & Dementia: Transl Res Clin Interventions. 2024;10(3):e12490.","journal-title":"Alzheimer's & Dementia: Transl Res Clin Interventions"},{"issue":"9","key":"1892_CR46","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1111\/ene.14999","volume":"28","author":"R Santangelo","year":"2021","unstructured":"Santangelo R, Agosta F, Masi F, Spinelli EG, Cecchetti G, Caso F, et al. Plasma neurofilament light chain levels and cognitive testing as predictors of fast progression in Alzheimer\u2019s disease. Eur J Neurol. 2021;28(9):2980\u20138.","journal-title":"Eur J Neurol"},{"issue":"4","key":"1892_CR47","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","volume":"78","author":"A Moscoso","year":"2021","unstructured":"Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero Rodr\u00edguez J, Snellman A, et al. Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol. 2021;78(4):396\u2013406.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1892_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70005","volume":"21","author":"F Pan","year":"2025","unstructured":"Pan F, Huang Q, Huang C, Lu Y, Cui L, Huang L, et al. Associations of hippocampal volumes, brain hypometabolism, and plasma NfL with amyloid, tau, and cognitive decline. Alzheimers Dement. 2025;21(2):e70005.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1892_CR49","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1212\/WNL.0000000000007767","volume":"93","author":"MM Mielke","year":"2019","unstructured":"Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Vemuri P, Skoog I, et al. Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology. 2019;93(3):e252-60.","journal-title":"Neurology"},{"issue":"1","key":"1892_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00944-y","volume":"13","author":"JD Marks","year":"2021","unstructured":"Marks JD, Syrjanen JA, Graff-Radford J, Petersen RC, Machulda MM, Campbell MR, et al. Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimers Res Ther. 2021;13(1):199.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"1892_CR51","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/jnnp-2022-330619","volume":"94","author":"D Altomare","year":"2023","unstructured":"Altomare D, Stampacchia S, Ribaldi F, Tomczyk S, Chevalier C, Poulain G, et al. Plasma biomarkers for Alzheimer\u2019s disease: a field-test in a memory clinic. J Neurol Neurosurg Psychiatry. 2023;94(6):420\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1892_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14458","author":"M Khalafi","year":"2024","unstructured":"Khalafi M, Dartora WJ, McIntire LBJ, Butler TA, Wartchow KM, Hojjati SH, et al. Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer\u2019s disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis. Alzheimers Dement. 2025 Feb;21(2):e14458. https:\/\/doi.org\/10.1002\/alz.14458","journal-title":"Alzheimers Dement"},{"key":"1892_CR53","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.5319","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1892_CR54","doi-asserted-by":"publisher","first-page":"828","DOI":"10.14283\/jpad.2023.83","volume":"10","author":"A Feizpour","year":"2023","unstructured":"Feizpour A, Dor\u00e9 V, Doecke JD, Saad ZS, Triana-Baltzer G, Slemmon R, et al. Two-year prognostic utility of plasma p217+tau across the Alzheimer\u2019s continuum. J Prev Alzheimers Dis. 2023;10(4):828\u201336.","journal-title":"J Prev Alzheimers Dis"},{"key":"1892_CR55","doi-asserted-by":"crossref","unstructured":"Insel PS, Mattsson-Carlgren N, Langford O, Caruso VM, Leuzy A, Young CB, et al. Concurrent changes in plasma phosphorylated Tau 217, Tau PET, and cognition in preclinical Alzheimer disease. JAMA Neurol. 2025. Available from: https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2838121. Cited 2025 Sep 17.","DOI":"10.1001\/jamaneurol.2025.2974"},{"issue":"1","key":"1892_CR56","volume":"17","author":"S De Meyer","year":"2025","unstructured":"De Meyer S, Blujdea ER, Schaeverbeke JM, Adamczuk K, Vandenberghe R, Poesen K, et al. Serum biomarkers as prognostic markers for Alzheimer\u2019s disease in a clinical setting. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2025;17(1):e70071.","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"issue":"20","key":"1892_CR57","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13024-025-00846-9","volume":"9","author":"W Youn","year":"2025","unstructured":"Youn W, Yun M, Lee CJ, Sch\u00f6ll M. Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases. Mol Neurodegener. 2025;9(20):54.","journal-title":"Mol Neurodegener"},{"key":"1892_CR58","doi-asserted-by":"publisher","unstructured":"Pichet Binette A, Smith R, Salvad\u00f3 G, Tideman P, Glans I, van Westen D, et al. Evaluation of the revised criteria for biological and clinical staging of Alzheimer disease. JAMA Neurol. 2025;82(7):666\u2013675. https:\/\/doi.org\/10.1001\/jamaneurol.2025.1100","DOI":"10.1001\/jamaneurol.2025.1100"}],"container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01892-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01892-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01892-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T17:03:28Z","timestamp":1762967008000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01892-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1892"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01892-7","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Danish Research Ethics Committee (H-21040317) and followed the tenets of the 1975 Helsinki Declaration. The study was registered at clinicaltrials.gov (NCT05175664). Written informed consent was obtained from each participant prior to enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AHS has served at scientific advisory board for Eisai\/BioArctic (renumeration paid to institution). KF serves or has served on a scientific advisory board and as scientific consultant for Novo Nordisk, Roche Diagnostics and Eisai, has given lectures in symposia for Novo Nordisk, Eli Lilly and Eisai\/BioArctic, (renumeration paid to institution) and has served or serves as principal investigator in trials for Roche, Biogen, AbbVie, Novo Nordisk and Roche Diagnostics (remuneration paid to institution). KF also serves as Editor-in-Chief for Alzheimer\u00b4s Research and Therapy (Springer) for which personal remuneration is paid. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD, is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, and is a shareholder of MicThera (outside submitted work). KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sunbird Bio, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The other authors have no conflict of interest to report.KF serves or has served on a scientific advisory board and as scientific consultant for Novo Nordisk, Roche Diagnostics and Eisai, has given lectures in symposia for Novo Nordisk, Eli Lilly and Eisai\/BioArctic, (renumeration paid to institution) and has served or serves as principal investigator in trials for Roche, Biogen, AbbVie, Novo Nordisk and Roche Diagnostics (remuneration paid to institution). KF also serves as Editor-in-Chief for Alzheimer\u00b4s Research and Therapy (Springer) for which personal remuneration is paid.HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD, is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, and is a shareholder of MicThera (outside submitted work).KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sunbird Bio, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.The other authors have no conflict of interest to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}